These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34879702)

  • 1. Utilization of Generic Cardiovascular Drugs in Medicare's Part D Program.
    Ma I; Tisdale RL; Vail D; Heidenreich PA; Sandhu AT
    Circ Cardiovasc Qual Outcomes; 2021 Dec; 14(12):e007559. PubMed ID: 34879702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
    Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
    Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
    Sacks CA; Lee CC; Kesselheim AS; Avorn J
    JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.
    Sumarsono A; Lalani HS; Vaduganathan M; Navar AM; Fonarow GC; Das SR; Pandey A
    JAMA Cardiol; 2021 Jan; 6(1):92-96. PubMed ID: 32902560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries.
    Sumarsono A; Sumarsono N; Das SR; Vaduganathan M; Agrawal D; Pandey A
    JAMA Netw Open; 2020 Feb; 3(2):e200181. PubMed ID: 32108893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
    Patel RA; Walberg MP; Tong E; Tan F; Rummel AE; Woelfel JA; Carr-Lopez SM; Galal SM
    J Manag Care Spec Pharm; 2014 Mar; 20(3):283-90. PubMed ID: 24564812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available.
    Dusetzina SB; Cubanski J; Nshuti L; True S; Hoadley J; Roberts D; Neuman T
    Health Aff (Millwood); 2020 Aug; 39(8):1326-1333. PubMed ID: 32744944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.
    Haas JS; Phillips KA; Gerstenberger EP; Seger AC
    Ann Intern Med; 2005 Jun; 142(11):891-7. PubMed ID: 15941695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
    Dickson SR; Kent T
    JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in the Use of Brand Name and Generic Medications and Total Prescription Cost Among Medicare Beneficiaries With Epilepsy.
    Terman SW; Lin CC; Kerr WT; DeLott LB; Callaghan BC; Burke JF
    Neurology; 2022 Aug; 99(8):e751-e761. PubMed ID: 35705496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Savings in Medicare Part D for Common Urological Conditions.
    Kirk PS; Borza T; Dupree JM; Wei JT; Ellimoottil C; Caram MEV; Burkhardt M; Heidelbaugh JJ; Hollenbeck BK; Skolarus TA
    Urol Pract; 2018 Sep; 5(5):351-359. PubMed ID: 30555855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.
    Fischer MA; Avorn J
    Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):207-14. PubMed ID: 15255087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) study.
    Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF; Fu J; Simien L; Tseng CW
    J Gen Intern Med; 2014 Jan; 29(1):230-6. PubMed ID: 23975059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016.
    Ross JS; Rohde S; Sangaralingham L; Brito JP; Choi L; Dutcher SK; Graham DJ; Jenkins MR; Lipska KJ; Mendoza M; Qiang Y; Wang Z; Wu Y; Yao X; Shah ND
    J Clin Endocrinol Metab; 2019 Jun; 104(6):2305-2314. PubMed ID: 30690529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicare Part D: Patients Bear The Cost Of 'Me Too' Brand-Name Drugs.
    Gastala NM; Wingrove P; Gaglioti A; Petterson S; Bazemore A
    Health Aff (Millwood); 2016 Jul; 35(7):1237-40. PubMed ID: 27385239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generic utilization and cost-sharing for prescription drugs.
    Gibson TB; McLaughlin CG; Smith DG
    Adv Health Econ Health Serv Res; 2010; 22():195-219. PubMed ID: 20575234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicare Part D Payments for Topical Steroids: Rising Costs and Potential Savings.
    Song H; Adamson A; Mostaghimi A
    JAMA Dermatol; 2017 Aug; 153(8):755-759. PubMed ID: 28453645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in brand and generic drug utilization for dermatology providers from 2013-2019.
    Mazmudar RS; Tripathi R; Bordeaux JS; Scott JF
    Arch Dermatol Res; 2023 May; 315(4):1041-1044. PubMed ID: 36309878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.